H.C. Wainwright assumed coverage of Xeris Biopharma (XERS) with a Buy rating and $10 price target The firm believes the commercial potential of the company’s commercial portfolio remains “meaningfully underappreciated.” The portfolio has the potential to drive further Xeris stock appreciation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS: